BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. announced that they have submitted its to the FDA for Motixafortide in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients.